The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Subgroup analysis of the EPCORE FL-1 trial: efficacy of epcoritamab plus R-squared in R/R FL
Benoit Tessoulin, MD, PhD, Nantes University Hospital Center, Nantes, France, discusses findings from a subgroup analysis of the Phase III EPCORE FL-1 trial (NCT05409066), highlighting that epcoritamab combined with lenalidomide and rituximab (R-squared) demonstrated a consistent benefit across various subgroups of patients with relapsed/refractory (R/R) follicular lymphoma (FL). Dr Tessoulin notes that the combination shows efficacy regardless of factors such as age, comorbidity burden, tumor size, number of prior lines of therapy, or baseline FLIPI score. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So you know that the FL1 trial did demonstrate an improvement over R-squared in the global population of the trial with a reduced hazard ratio of 0.21. So the basic idea of the subgroup analysis was to see whether this would hold in low and high risk patients. So when you look at the age of the patients, the comorbidity burden, the size of the tumor, the number of lines, the POD24 events or not, the FLIPI score at baseline, what you can see is that all those subgroups of analysis, they achieve the very same hazard ratio of Epco plus R-squared compared to R-squared...
So you know that the FL1 trial did demonstrate an improvement over R-squared in the global population of the trial with a reduced hazard ratio of 0.21. So the basic idea of the subgroup analysis was to see whether this would hold in low and high risk patients. So when you look at the age of the patients, the comorbidity burden, the size of the tumor, the number of lines, the POD24 events or not, the FLIPI score at baseline, what you can see is that all those subgroups of analysis, they achieve the very same hazard ratio of Epco plus R-squared compared to R-squared. So the main takeaway was that all the subgroups are having benefit from this new combination in regard to R-squared. And we did have a quick look to the toxicity rates too. And what was quite striking is that no matter how much comorbidity you had on the NHL5 score, the patients did the same in terms of adverse events. So all in all, a pretty all comer combination.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Advisory/Consultancy: AbbVie, Ascentage, AstraZeneca, BeiGene, Genmab, Janssen, Lilly, Roche; Travel Accommodation: AbbVie, Kite Gilead, AstraZeneca, Roche, Janssen, Lilly.
